450 related articles for article (PubMed ID: 25871331)
1. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients.
Catalano OA; Nicolai E; Rosen BR; Luongo A; Catalano M; Iannace C; Guimaraes A; Vangel MG; Mahmood U; Soricelli A; Salvatore M
Br J Cancer; 2015 Apr; 112(9):1452-60. PubMed ID: 25871331
[TBL] [Abstract][Full Text] [Related]
2. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
[TBL] [Abstract][Full Text] [Related]
3. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
[TBL] [Abstract][Full Text] [Related]
4. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.
Dashevsky BZ; Goldman DA; Parsons M; Gönen M; Corben AD; Jochelson MS; Hudis CA; Morrow M; Ulaner GA
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1666-1673. PubMed ID: 25971426
[TBL] [Abstract][Full Text] [Related]
5. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
6. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.
Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA
Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
12. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A
Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
14. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
15. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management.
Piperkova E; Raphael B; Altinyay ME; Castellon I; Libes R; Sandella N; Heiba S; Abdel-Dayem H
Clin Nucl Med; 2007 Jun; 32(6):429-34. PubMed ID: 17515747
[TBL] [Abstract][Full Text] [Related]
16. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
[TBL] [Abstract][Full Text] [Related]
17. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
18. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
[TBL] [Abstract][Full Text] [Related]
19. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
20. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
